Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Myeloma in Relapse”

1,377 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,377 results

Testing effectiveness (Phase 2)Ended earlyNCT03215030
What this trial is testing

Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Teva Branded Pharmaceutical Products R&D LLC 272
Testing effectiveness (Phase 2)WithdrawnNCT02115035
What this trial is testing

A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib

Who this might be right for
Multiple Myeloma
University of Arkansas
Large-scale testing (Phase 3)Study completedNCT03275285
What this trial is testing

Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients

Who this might be right for
Plasma Cell Myeloma
Sanofi 302
Early research (Phase 1)Study completedNCT01965353
What this trial is testing

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in Relapse
Dana-Farber Cancer Institute 21
Not applicableNot Yet RecruitingNCT06825845
What this trial is testing

Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy

Who this might be right for
Relapsed or Refractory Multiple Myeloma
CARsgen Therapeutics Co., Ltd. 1,500
Not applicableStudy completedNCT02970747
What this trial is testing

Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma in Relapse
iOMEDICO AG 359
Not applicableNo Longer AvailableNCT02856438
What this trial is testing

Early Patient Access Treatment Use Protocol CA204-220

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Ended earlyNCT05191472
What this trial is testing

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Alfred Chung, MD 3
Testing effectiveness (Phase 2)Study completedNCT00721734
What this trial is testing

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Who this might be right for
Multiple MyelomaRenal Insufficiency
Amgen 50
Testing effectiveness (Phase 2)Study completedNCT01053949
What this trial is testing

IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

Who this might be right for
Multiple Myeloma
University Hospital, Lille 84
Early research (Phase 1)Active Not RecruitingNCT05431608
What this trial is testing

MCARH109 and MCARH125 in People With Multiple Myeloma

Who this might be right for
Multiple MyelomaRefractory Multiple MyelomaRelapse Multiple Myeloma
Memorial Sloan Kettering Cancer Center 15
Early research (Phase 1)Ended earlyNCT02579824
What this trial is testing

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 14
Early research (Phase 1)Ended earlyNCT00996359
What this trial is testing

Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Medicine and Dentistry of New Jersey 4
Testing effectiveness (Phase 2)Study completedNCT01394354
What this trial is testing

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma in Relapse
University Hospital Freiburg 34
Testing effectiveness (Phase 2)Study completedNCT00474929
What this trial is testing

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Who this might be right for
LymphomaMultiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 103
Testing effectiveness (Phase 2)Ended earlyNCT01464034
What this trial is testing

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Criterium, Inc. 136
Testing effectiveness (Phase 2)Ended earlyNCT00648739
What this trial is testing

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaMultiple Myeloma
Alexion Pharmaceuticals, Inc. 26
Very early researchLooking for participantsNCT07249073
What this trial is testing

CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04649073
What this trial is testing

Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Otsuka Pharmaceutical Co., Ltd. 11
Testing effectiveness (Phase 2)Study completedNCT01319422
What this trial is testing

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Yale University 40
Load More Results